Mentice AB (DE:MN2)
FRANKFURT:MN2
MN2 Stock Chart & Stats
€1.20
€0.00(0.00%)
At close: 4:00 PM EST
€1.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.80 - €1.87
Previous CloseN/A
Volume0.00
Average Volume (3M)106.00
Market Cap
€36.22M
Enterprise Value€353.00M
Total Cash (Recent Filing)€56.22M
Total Debt (Recent Filing)€15.46M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Jul 23, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding28,125,734
10 Day Avg. Volume0
30 Day Avg. Volume106
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)2.71
Price to Sales (P/S)1.34
P/FCF Ratio-14.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€28.46M
Bulls Say, Bears Say
Bulls Say
Margin Recovery & EBITDA PositivityGross margin recovery to ~40% alongside EBITDA turning positive indicates the core simulation business is achieving better pricing, mix or cost control. Sustained margin expansion creates operating leverage that improves cash generation potential and funds R&D and commercial scale over the next several quarters.
Operating Cash-flow TurnaroundPositive operating cash flow (~9.8m) shows the company is converting operations into real cash, reducing near-term financing needs. Improved working-capital dynamics and cash generation support continued investment in content, upgrades and customer deployments, strengthening medium-term sustainability.
Conservative Balance Sheet / Low LeverageLow debt-to-equity (~0.13) and declining debt provide financial flexibility to fund product development, sales expansion and content creation without large interest burdens. Conservative leverage reduces refinancing risk while the business pursues recurring-license and B2B growth.
Bears Say
Still Loss-making / Negative Net MarginDespite operational improvements, the firm still reports a negative operating margin and ~-7% net margin. Continued losses limit return on capital and may require external funding or dilution if profitability doesn't become consistent, constraining long-term shareholder returns.
Inconsistent Free Cash FlowFree cash flow remains slightly negative and showed sharp deterioration versus 2025, indicating cash conversion is not yet steady. Persistently negative or volatile FCF constrains reinvestment capacity and increases reliance on financing, raising medium-term execution risk.
Weak Shareholder Returns / ROENegative return on equity across reported periods signals that current earnings are insufficient to deliver shareholder value. Persistent ROE weakness reflects ongoing profitability challenges and undermines confidence in sustained capital efficiency as the company scales.
Mentice AB News
MN2 FAQ
What was Mentice AB’s price range in the past 12 months?
Mentice AB lowest stock price was €0.80 and its highest was €1.87 in the past 12 months.
What is Mentice AB’s market cap?
Mentice AB’s market cap is €36.22M.
When is Mentice AB’s upcoming earnings report date?
Mentice AB’s upcoming earnings report date is Jul 23, 2026 which is in 44 days.
How were Mentice AB’s earnings last quarter?
Mentice AB released its earnings results on May 07, 2026. The company reported -€0.064 earnings per share for the quarter, missing the consensus estimate of -€0.023 by -€0.042.
Is Mentice AB overvalued?
According to Wall Street analysts Mentice AB’s price is currently Overvalued.
Does Mentice AB pay dividends?
Mentice AB does not currently pay dividends.
What is Mentice AB’s EPS estimate?
Mentice AB’s EPS estimate is >-0.01.
How many shares outstanding does Mentice AB have?
Mentice AB has 28,125,734 shares outstanding.
What happened to Mentice AB’s price movement after its last earnings report?
Mentice AB reported an EPS of -€0.064 in its last earnings report, missing expectations of -€0.023. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mentice AB?
Currently, no hedge funds are holding shares in DE:MN2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mentice AB
Mentice AB (publ), founded in 1998 and headquartered in Gothenburg, Sweden, specializes in delivering advanced endovascular simulation solutions. These are utilized by educational institutions, healthcare systems, and medical device manufacturers globally, with the company's operations spanning across Europe, the Middle East, Africa, the Asia Pacific region, and the Americas. Its business is structured across distinct segments focusing on the Medical Device Industry, Healthcare Systems, and Strategic Alliances. The company offers a comprehensive suite of software modules designed for training in a wide array of interventional procedures. These include acute ischemic stroke, atrial septal defect/patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee, carotid, and renal interventions, along with patient-specific simulations. The portfolio further encompasses advanced and essential coronary procedures, intermediate coronary, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic and uterine artery embolization, radiation safety, transarterial chemoembolization, transseptal puncture, vascular trauma, and cardiac rhythm management. Additionally, Mentice provides crucial support for interventionalists transitioning from transfemoral to transradial access techniques. Beyond software, Mentice's product line features sophisticated medical simulators for endovascular therapies, accompanied by compatible accessories and extensions. They also supply specialized silicone vasculature, as well as cardiac, vascular, and neurovascular flow systems. Innovative digital offerings include the Mentice Right Heart Cath App, a mobile tool for interactive exploration of right heart catheterization procedures, and the Mentice Live Learning Center, which facilitates remote learning through its VIST G endovascular simulation platform. All these comprehensive solutions are engineered to educate, train, and significantly enhance the skills of medical professionals.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
Bactiguard Holding AB
―
C-Rad AB Class B
―
Acarix AB
―
BrainCool AB
―